Talphera, Inc. [Formerly AcelRx Pharmaceuticals, Inc., Nasdaq: ACRX, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain.] is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. This release is intended for investors only. Talphera will begin trading on Nasdaq under the trading symbol "TLPH" effective January 10, 2024